Dynamin 3: A new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1417-1424

  Inokawa, Yoshikuni ^a   Nomoto, Shuji ^a   Hishida, Mitsuhiro ^a   Hayashi, Masamichi ^a   Kanda, Mitsuro ^a   Nishikawa, Yoko ^a   Takeda, Shin ^b   Fujiwara, Michitaka ^a   Koike, Masahiko ^a   Sugimoto, Hiroyuki ^a   Fujii, Tsutomu ^a   Nakayama, Goro ^a   Yamada, Suguru ^a   Tanaka, Chie ^a   Kobayashi, Daisuke ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

DNM3; Hepatocellular carcinoma; Methylation; Triple combination array

Indexed keywords

DYNAMIN III;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHROMOSOME 1Q; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; DYNAMIN 3 GENE; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 84886884173     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S51913     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245-1255.
3. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210(3):655-661.
4. Takayasu K, Arii S, Ikai I, et al; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131(2):461-469.
5. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
6. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S72-S78.
7. Cusnir M, Patt YZ. Novel systemic therapy options for hepatocellular carcinoma. Cancer J. 2004;10(2):97-103.
8. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7): 2557-2576.
9. Kanda M, Nomoto S, Okamura Y, et al. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 2009;35(3):477-483.
10. Nomoto S, Kanda M, Okamura Y, et al. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol. 2010;17(3): 923-932.
11. Okamura Y, Nomoto S, Kanda M, et al. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett. 2010;289(2): 170-177.
12. Okamura Y, Nomoto S, Kanda M, et al. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol. 2011;18(2):572-579.
13. Kanda M, Nomoto S, Okamura Y, et al. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 2011;50(8):571-579.
14. Hayashi M, Nomoto S, Kanda M, et al. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. J Surg Oncol. 2012;105(4):381-386.
15. Okamura Y, Nomoto S, Hayashi M, et al. Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. Cancer Lett. 2011;312(2):150-157.
16. Hishida M, Nomoto S, Inokawa Y, et al. Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. Int J Oncol. 2013;43(1):88-94.
17. Orth JD, McNiven MA. Dynamin at the actin-membrane interface. Curr Opin Cell Biol. 2003;15(1):31-39.
18. Booken N, Gratchev A, Utikal J, et al. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia. 2008;22(2):393-399.
19. Teicher BA. Searching for molecular targets in sarcoma. Biochem Pharmacol. 2012;84(1):1-10.
20. Bibikova M, Fan JB. GoldenGate assay for DNA methylation profiling. Methods Mol Biol. 2009;507:149-163.
21. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol (Gedrukt). 2003;3(3):235-240.
22. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28(1):29-35.
23. Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999; 59(1):71-73.
24. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 2003;163(3):1101-1107.
25. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003;163(4):1371-1378.
26. Sever S. Dynamin and endocytosis. Curr Opin Cell Biol. 2002;14(4): 463-467.
27. Shen J, Wang S, Zhang YJ, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology. 2012;55(6):1799-1808.
28. Lee YY, Do IG, Park YA, et al. Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix. Cancer Biol Ther. 2010;10(4):329-335.
29. Devarajan P, Johnston JJ, Ginsberg SS, Van Wart HE, Berliner N. Structure and expression of neutrophil gelatinase cDNA. Identity with type IV collagenase from HT1080 cells. J Biol Chem. 1992;267(35):25228-25232.
30. Gao J, Ding F, Liu Q, Yao Y. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem. 2013;376(1-2):21-32.
31. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-174.
32. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9-34.
33. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100(8):2957-2964.
34. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.